Toray Of Japan Accelerates Anti-Itching Agent Clinical Trails In Europe And U.S.
This article was originally published in PharmAsia News
Executive Summary
Currently under approval review in Japan, Toray has sped up the clinic trials overseas for anti-itching agent TRK-820, jointly developed by Toray, Japan Tobacco, Torii Pharma and Maruo Co. In Europe, TRK-820 injection has entered a Phase III trial, and a Phase III trial for TRK-820 oral dose has begun in the U.S. TRK-820 is an opioid k receptor agonist for treating uremic pruritis in hemodialysis patients. Toray hopes to get TRK-820 oral dose approved in Japan within this year. The company also announced that urinary incontinence drug TRK-130 has entered Phase II trials in Japan. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.